The hormones in dosage market (excluding contraceptives and antibiotics) in the Czech Republic experienced fluctuations in recent years. By 2023, the value per capita reached $38.24. From 2021 to 2022, the market saw a 7.68% decrease, while from 2022 to 2023, there was an increase of 1.51%. The compound annual growth rate (CAGR) over the past five years was approximately 1.66%, indicating a steady albeit modest upward trend.
Future trends to watch for include:
- Continued developments in healthcare policies and reimbursement mechanisms.
- Potential innovations in hormone-related therapies impacting demand.
- Demographic changes and aging population, influencing market dynamics.
